Clinical trials
First-Line clinical trials
Below are recruiting first-line clinical trials, each written for real people, not researchers. We’re tracking 406 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07778212Recruiting
New drug combo for aggressive lymphoma
This trial tests a new combination of drugs for people newly diagnosed with an aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The combo includes orelabrutinib plus standard chemo-immunotherapy, and may help improve outcomes for those at intermediate or high risk.
Xiamen, FujianAges 18 years+ - NCT06768307RecruitingPhase 2
Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06278870RecruitingPhase 3
New drug combo vs standard for HER2+ advanced breast cancer
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
Guangzhou, GuangdongAges 18–75 - NCT07232875RecruitingPhase 3
New drug combo for first-line advanced pancreatic cancer
This trial tests a new drug (HRS-4642) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has spread. It may help shrink tumors and extend life.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07117435RecruitingPhase 1
Targeted chemo into liver for colorectal cancer spread
This trial is testing a new way to give the chemotherapy drug paclitaxel directly into the liver (through a tiny tube) along with standard systemic treatment for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to see if this targeted approach works better than standard treatment alone.
Lishui, ZhejiangAges 18–75 - NCT07407231Recruiting
Chemo and radiation for advanced inoperable pancreatic cancer
This trial tests a combined treatment of chemotherapy followed by a precise type of radiation therapy (SBRT) for people with pancreatic cancer that cannot be surgically removed. It is designed for those who have not yet started treatment for locally advanced disease.
LjubljanaAges 18 years+ - NCT06405490RecruitingPhase 2
Chemo plus immunotherapy for first-line advanced pancreatic cancer
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07207278Recruiting
Genetics and immune study of lung signet ring cell cancer
This research study is looking at the unique genetic makeup and immune features of a rare type of lung cancer called signet ring cell carcinoma. By studying tumor samples and medical data, researchers hope to find better ways to understand and eventually treat this cancer.
Hangzhou, ZhejiangAges 18–85 - NCT06830018Recruiting
New megestrol for advanced stomach or colon cancer with fatigue
This study tests a new form of megestrol (a medicine that can boost appetite and energy) for people with advanced stomach or colorectal cancer who also have fatigue and poor appetite. It is given as a first treatment, meaning you haven't had chemotherapy yet for your advanced cancer.
Shenyang, LiaoningAges 18–75 - NCT07238283RecruitingPhase 3
New liposome chemo combo for first-line pancreatic cancer
This trial tests a new form of chemotherapy (irinotecan liposome) combined with two other chemo drugs, compared to a standard treatment, for people with metastatic pancreatic cancer who haven't had chemo yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT05894694RecruitingPhase 4
Testing Compound Kushen injection for advanced colon cancer survival
This trial studies whether Compound Kushen injection can improve survival in people with advanced colorectal cancer. It’s aimed at people starting first-line treatment, and only includes certain cancer and health situations to keep results clear.
BeijingAges 18 years+ - NCT07633353Enrolling by invitation
Real-World Outcomes of a New Treatment for Advanced Kidney Cancer
This study looks at how well two newer cancer drugs (enfortumab vedotin and pembrolizumab) work together for advanced upper tract urothelial carcinoma—a rare kidney cancer. Researchers are collecting information from hospitals in France to understand how patients respond and what side effects occur in everyday care.
NîmesAges 18 years+ - NCT03322995RecruitingPhase 2
Neoadjuvant chemo study for resectable pancreatic cancer
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Milwaukee, WisconsinAges 18 years+ - NCT04335292RecruitingPhase 2
Osimertinib then chemotherapy for EGFR-mutated lung cancer
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Vancouver, British ColumbiaAges 18 years+ - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+ - NCT05970302RecruitingPhase 2
XELOX, bevacizumab, and immunotherapy for metastatic colon cancer
This Phase 2 trial studies a combination treatment (XELOX plus bevacizumab plus an immunotherapy drug) for people with metastatic colon cancer that has certain lab features (MSS/pMMR and RAS-mutated). It aims to see how well the treatment works as a first treatment when the cancer cannot be removed with surgery.
BeijingAges 18 years+ - NCT06148779Recruiting
Digital first-line OA treatment for equal access
This study looks at whether a digital program for osteoarthritis (OA) of the hip or knee helps more people get the care they need. It tests if the program works well and is fair for everyone.
MalmöAges 18 years+ - NCT06487585RecruitingPhase 4
Angiotensin II as first pressor after heart surgery
This trial tests if starting Angiotensin II early, instead of other blood pressure medications, can help heart surgery patients maintain safe blood pressure. It may be an option if you have low blood pressure after surgery despite receiving fluids.
Towson, MarylandAges 18 years+ - NCT06619288Recruiting
HIV treatment study comparing B/F/TAF to older drugs
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
Nantong, JiangsuAges 18 years+ - NCT06751914Recruiting
Vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751940Recruiting
Personalized vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
Nanchang, JiangxiAges 18–70 - NCT06841055RecruitingPhase 2
Pumitamig plus chemo for Stage IV lung cancer after immunotherapy
This trial tests a new investigational drug called Pumitamig (BNT327) given with chemotherapy for people with advanced non-small cell lung cancer (Stage IV) that has continued to grow after one prior treatment with immunotherapy and platinum chemotherapy. The study aims to see if this combination is safe and can help shrink the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06841172RecruitingPhase 3
Radiation vs treatment switch for limited liver cancer growth
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
Jinan, ShandongAges 18–75 - NCT06870942RecruitingPhase 2
Radiation therapy for liver cancer that progresses after first immunotherapy
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new First-Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line?
- Yes. Clin2 currently lists 406 recruiting first-line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.